RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Reimbursement in China

Reimbursement in China

Posted 01 October 2010

The global recession has left medical companies scrambling to find new markets. China's gross domestic product, adjusted for purchasing power parity, is currently second in the world and has surpassed Japan's. Medical companies should focus on this growing market. However, before entering the Chinese market, it is essential to investigate the market potential and determine reimbursement for your specific medical product. This article will cover the basics of healthcare in China and how to determine reimbursement for drugs, medical devices and in vitro diagnostics in that marketplace.


© 2022 Regulatory Affairs Professionals Society.